Go Pro
Laura Chico

Laura Chico Analyst Performance

Managing Director, Equity Research at Wedbush

Laura Chico is a stock analyst at Wedbush focused in the healthcare sector, covering 35 publicly traded companies. Over the past year, Laura Chico has issued 98 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Laura Chico's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Laura Chico's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
153 Last 8 Years
Buy Recommendations
73.86% 113 Buy Ratings
Companies Covered
35 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.7%1 ratings
Buy73.2%111 ratings
Hold22.2%34 ratings
Sell3.9%6 ratings

Out of 153 total stock ratings issued by Laura Chico at Wedbush, the majority (73.2%) have been Buy recommendations, followed by 22.2% Hold, 3.9% Sell, and 0.7% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
88.6% of companies on NASDAQ
31 companies
NYSE
8.6% of companies on NYSE
3 companies
OTCMKTS
2.9% of companies on OTCMKTS
1 company

Laura Chico, an analyst at Wedbush, currently covers 35 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
33 companies
94.3%
Consumer Discretionary
1 company
2.9%
Technology
1 company
2.9%

Laura Chico of Wedbush specializes in stock coverage within the Healthcare sector, with additional focus on Consumer Discretionary and Technology companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
26 companies
74.3%
PHARMACEUTICALS
7 companies
20.0%
HOUSEHOLD DURABLES
1 company
2.9%
SOFTWARE
1 company
2.9%

About Laura Chico

Laura brings more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in Equity Research. During her career, Laura has served as Vice President Equity Research at Raymond James, and as a biotech analyst in the Robert W. Baird Equity Research Healthcare group. Before entering equity research, Laura held scientific roles in both industry and academic settings with focus in central nervous system (“CNS”) diseases such as Alzheimer’s disease. Laura received her B.S. in Bacteriology from the University of Wisconsin-Madison, her M.S. in Computational Biology & Bioinformatics, and her Ph.D. in Molecular Pharmacology, from Northwestern University. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.
Follow on LinkedIn

Laura Chico's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
10/1/2026Reiterated Rating$14.05$47.00Outperform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
9/23/2026Reiterated Rating$28.38$48.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9/22/2026Reiterated Rating$62.86$76.00Outperform
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
9/18/2026Lower Price Target$44.08$55.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
9/15/2026Boost Price Target$7.36$6.00Neutral
Pharvaris N.V. stock logo
PHVS
Pharvaris
9/9/2026Boost Price Target$37.68$50.00Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
9/8/2026Reiterated Rating$35.25$42.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
9/3/2026Lower Price Target$26.53$23.00Neutral
Climb Bio, Inc. stock logo
CLYM
Climb Bio
8/19/2026Reiterated Rating$17.39$20.00Outperform
Ardelyx, Inc. stock logo
ARDX
Ardelyx
8/18/2026Reiterated Rating$4.06$9.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
8/17/2026Reiterated Rating$31.63$34.00Neutral
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
8/13/2026Boost Price Target$29.12$26.00Neutral
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
8/11/2026Lower Price Target$30.76$34.00Neutral
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
8/10/2026Boost Price Target$21.95$47.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
8/10/2026Downgrade$4.08$5.00Neutral
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
8/6/2026Boost Price Target$64.22$75.00Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
8/6/2026Lower Price Target$9.43$20.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
8/5/2026Lower Price Target$4.11$11.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8/5/2026Boost Price Target$110.92$122.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/4/2026Boost Price Target$29.56$40.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
8/3/2026Boost Price Target$166.80$194.00Outperform
Biogen Inc. stock logo
BIIB
Biogen
7/30/2026Boost Price Target$206.17$215.00Neutral
Climb Bio, Inc. stock logo
CLYM
Climb Bio
7/27/2026Boost Price Target$12.84$20.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
7/13/2026Reiterated Rating$25.64$26.00Outperform
Biogen Inc. stock logo
BIIB
Biogen
7/13/2026Reiterated Rating$202.06$201.00Neutral
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
7/8/2026Boost Price Target$42.96$43.00Neutral
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
6/30/2026Boost Price Target$18.79$43.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
6/22/2026Boost Price Target$55.15$61.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
6/12/2026Reiterated Rating$11.12$17.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
6/3/2026Reiterated Rating$42.94$55.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
6/2/2026Boost Price Target$18.59$45.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
6/2/2026Lower Price Target$303.77$162.00Underperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
6/1/2026Boost Price Target$40.26$52.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
5/18/2026Lower Price Target$3.58$12.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
5/14/2026Boost Price Target$22.94$24.00Neutral
PepGen, Inc. stock logo
PEPG
PepGen
5/13/2026Lower Price Target$1.61$4.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/13/2026Lower Price Target$7.78$16.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
5/11/2026Boost Price Target$25.81$34.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
5/8/2026Boost Price Target$11.94$17.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
5/8/2026Boost Price Target$334.73$166.00Underperform
The end may be near for these iconic stocks (Ad)

Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel

Watch Marc Chaikin's free presentation and get his full buy-and-sell list today
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/8/2026Lower Price Target$19.89$23.00Outperform
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
5/7/2026Lower Price Target$8.66$21.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
5/6/2026Boost Price Target$90.24$105.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5/6/2026Lower Price Target$25.01$26.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
5/6/2026Boost Price Target$135.06$176.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/5/2026Boost Price Target$44.91$55.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5/5/2026Initiated Coverage$40.45$53.00Outperform
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5/4/2026Upgrade$40.97Strong-Buy
Biogen Inc. stock logo
BIIB
Biogen
4/30/2026Boost Price Target$194.38$196.00Neutral
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4/15/2026Reiterated Rating$2.96$7.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4/14/2026Boost Price Target$41.18$44.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
4/8/2026Lower Price Target$13.96$31.00Outperform
Pharvaris N.V. stock logo
PHVS
Pharvaris
4/7/2026Boost Price Target$28.37$42.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4/7/2026Boost Price Target$132.48$166.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
4/2/2026Lower Price Target$20.41$21.00Neutral
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3/31/2026Lower Price Target$18.82$37.00Outperform
PepGen, Inc. stock logo
PEPG
PepGen
3/31/2026Lower Price Target$1.44$5.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3/20/2026Boost Price Target$4.47$13.00Outperform
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/20/2026Boost Price Target$2.30$7.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
3/17/2026Reiterated Rating$29.78$32.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3/17/2026Boost Price Target$33.96$38.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
3/17/2026Boost Price Target$24.27$22.00Neutral
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3/16/2026Lower Price Target$55.23$63.00Outperform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3/16/2026Boost Price Target$50.21$58.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3/11/2026Reiterated Rating$29.19$44.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3/11/2026Reiterated Rating$8.18$14.00Outperform
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3/10/2026Boost Price Target$62.76$64.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/10/2026Boost Price Target$79.23$80.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
3/9/2026Reiterated Rating$14.05$24.00Outperform
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3/5/2026Initiated Coverage$7.28$12.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3/3/2026Boost Price Target$5.36$12.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2/25/2026Reiterated Rating$3.69$11.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2/25/2026Lower Price Target$22.13$18.00Neutral
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
2/24/2026Reiterated Rating$33.60$80.00Neutral
Ardelyx, Inc. stock logo
ARDX
Ardelyx
2/23/2026Reiterated Rating$5.73$19.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
2/20/2026Boost Price Target$331.61$130.00Underperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2/17/2026Reiterated Rating$20.66$25.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/12/2026Boost Price Target$126.00$151.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2/11/2026Boost Price Target$49.44$55.00Outperform
Biogen Inc. stock logo
BIIB
Biogen
2/9/2026Boost Price Target$201.18$187.00Neutral
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1/21/2026Boost Price Target$7.76$19.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
1/12/2026Boost Price Target$32.85$36.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
1/12/2026Boost Price Target$288.45$95.00Underperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
12/22/2025Reiterated Rating$42.44$46.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
12/11/2025Boost Price Target$44.34$33.00Neutral
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12/11/2025Lower Price Target$17.49$30.00Outperform
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
12/10/2025Boost Price Target$31.80$47.00Outperform
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
12/5/2025Boost Price Target$20.11$31.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
12/5/2025Reiterated Rating$189.97$83.00Underperform
Ardelyx, Inc. stock logo
ARDX
Ardelyx
11/25/2025Downgrade$5.50Hold
Trump's New Dollar (Ad)

Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel

Watch the free briefing and see the three steps to prepare today
Pharvaris N.V. stock logo
PHVS
Pharvaris
11/13/2025Boost Price Target$26.13$30.00Outperform
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
11/7/2025Boost Price Target$29.21$36.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
11/7/2025Lower Price Target$17.58$32.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
11/6/2025Boost Price Target$33.73$46.00Outperform
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
11/6/2025Boost Price Target$164.64$77.00Underperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
11/5/2025Boost Price Target$21.20$32.00Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
10/15/2025Set Price Target$11.61$13.00Neutral
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
10/15/2025Downgrade$11.92$13.00Neutral
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
9/30/2025Lower Price Target$3.38$11.00Outperform
PepGen, Inc. stock logo
PEPG
PepGen
9/25/2025Boost Price Target$5.97$9.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
9/22/2025Reiterated Rating$146.62Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
9/12/2025Boost Price Target$37.86$44.00Outperform
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/9/2025Downgrade$30.18$48.00Neutral
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8/21/2025Boost Price Target$23.72$42.00Outperform
Jade Biosciences, Inc. stock logo
JBIO
Jade Biosciences
8/14/2025Boost Price Target$7.03$18.00Outperform
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
8/13/2025Lower Price Target$6.15$14.00Outperform
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/13/2025Boost Price Target$15.66$22.00Outperform
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
8/12/2025Boost Price Target$36.10$43.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
8/7/2025Boost Price Target$17.24$32.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
8/6/2025Boost Price Target$157.20$400.00Outperform
Ardelyx, Inc. stock logo
ARDX
Ardelyx
8/5/2025Reiterated Rating$5.08$14.00Outperform
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
7/31/2025Boost Price Target$136.76$141.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
7/14/2025Lower Price Target$29.51$34.00Neutral
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
7/8/2025Initiated Coverage$12.12$17.00Outperform
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
6/24/2025Lower Price Target$2.76$15.00Outperform
Lennar Corporation stock logo
LEN
Lennar
6/18/2025Reiterated Rating$105.15$130.00Neutral
Biogen Inc. stock logo
BIIB
Biogen
6/12/2025Reiterated Rating$132.63$121.00Neutral
Pharvaris N.V. stock logo
PHVS
Pharvaris
6/5/2025Reiterated Rating$16.88$27.00Outperform
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/16/2025Reiterated Rating$17.51$30.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
5/16/2025Reiterated Rating$86.00$320.00Outperform
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
5/15/2025Reiterated Rating$2.26$4.00Neutral
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
5/7/2025Lower Price Target$14.02$30.00Outperform
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
5/7/2025Lower Price Target$22.33$26.00Neutral
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/2/2025Reiterated Rating$20.56$30.00Outperform
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
4/21/2025Reiterated Rating$13.67$43.00Outperform
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3/14/2025Reiterated Rating$107.60$320.00Outperform
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3/12/2025Reiterated Rating$0.49$3.00Outperform
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3/12/2025Reiterated Rating$6.47$28.00Outperform
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/12/2025Reiterated Rating$22.69$36.00Outperform
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
3/6/2025Initiated Coverage$12.90$42.00Outperform
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
3/3/2025Lower Price Target$25.15$29.00Neutral
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2/7/2025Lower Price Target$121.12$147.00Outperform
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1/13/2025Reiterated Rating$41.84$48.00Neutral